87 completed, 20 active not recruiting, 17 recruiting, 9 terminated. 61 Phase 1, 52 Phase 2, 29 Phase 3, 8 Phase 4, 1 Early Phase 1.
Follow ModernaTX, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Updated mRNA Seasonal Influenza Vaccines mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine - Seasonal Influenza | Phase 4 | Not yet recruiting | ModernaTX, Inc. | 200 | 2026-10-15 | 2026-10-20 |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations mRNA-1273, mRNA-1283 - SARS-CoV-2 | Phase 4 | Not yet recruiting | ModernaTX, Inc. | 300 | 2026-10-09 | 2026-10-07 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children mRNA-1010, Fluarix Trivalent - Seasonal Influenza | Phase 1 | Not yet recruiting | ModernaTX, Inc. | 96 | 2026-10-07 | 2026-10-13 |
| Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years mCombriax® (mRNA-1083), Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) - COVID-19, Influenza | Phase 4 | Not yet recruiting | Tor Biering-Sørensen | 410000 | 2026-09-01 | 2026-08-27 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age mRNA-1283, mRNA-1273 - SARS-CoV-2 | Phase 2 | Not yet recruiting | ModernaTX, Inc. | 300 | 2026-09-01 | 2026-09-09 |
| A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3) - Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV) | Phase 1 | Recruiting | ModernaTX, Inc. | 375 | 2026-08-11 | 2026-08-19 |
| A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants mRNA-1469, Placebo - Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | Phase 1 | Active not recruiting | ModernaTX, Inc. | 84 | 2026-07-31 | 2026-09-24 |
| A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 876 | 2026-05-04 | 2026-10-19 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) mRNA-1982, Placebo - Lyme Disease | Phase 2 | Active not recruiting | ModernaTX, Inc. | 366 | 2026-04-29 | 2026-08-03 |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults mRNA-1018-H5, Placebo - Influenza | Phase 3 | Active not recruiting | ModernaTX, Inc. | 4050 | 2026-03-23 | 2026-08-11 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age mRNA-1189 - Epstein-Barr Virus | Phase 1 | Recruiting | ModernaTX, Inc. | 120 | 2026-03-17 | 2026-03-24 |
| Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. mRNA-1645-eODGT8, mRNA-1645-CoreG28v2, mRNA-1645-N332GT5 - HIV Infections | Phase 1 | Active not recruiting | International AIDS Vaccine Initiative | 96 | 2025-12-15 | 2026-07-01 |
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) Intismeran Autogene, Pembrolizumab, Carboplatin - Squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 180 | 2025-12-12 | 2026-10-01 |
| Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 mRNA-1273 (Moderna COVID-19 vaccine) - COVID-19 | Phase 4 | Completed | Tor Biering-Sørensen | 41060 | 2025-12-11 | 2026-10-06 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) mRNA-1273, mRNA-1283, Placebo - SARS-CoV-2 | Phase 4 | Active not recruiting | ModernaTX, Inc. | 30000 | 2025-11-26 | 2026-09-28 |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma mRNA-2808 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | ModernaTX, Inc. | 190 | 2025-09-30 | 2026-09-23 |
| A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age mRNA-1345 - Respiratory Syncytial Virus | Phase 3 | Completed | ModernaTX, Inc. | 507 | 2025-08-05 | 2026-05-04 |
| ACTengine® IMA203 Combined With mRNA-4203 IMA203, mRNA-4203 - Cutaneous Melanoma, Synovial Sarcoma | Phase 1 | Recruiting | Immatics US, Inc. | 15 | 2025-07-25 | 2026-01-08 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations mRNA-1283.251 Variant-containing Formulation - COVID-19 | Phase 4 | Completed | ModernaTX, Inc. | 832 | 2025-07-21 | 2026-07-07 |
| A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years mRNA-1195, Placebo - Multiple Sclerosis | Phase 2 | Recruiting | ModernaTX, Inc. | 180 | 2025-04-16 | 2026-06-15 |
Showing 20 of 145. Sign in to see all of them.
Virus Diseases (47) · COVID-19 (43) · Coronavirus Infections (31) · Influenza, Human (24) · Cytomegalovirus Infections (9) · Metabolism, Inborn Errors (6) · DNA Virus Infections (5) · Genetic Diseases, Inborn (5) · Recurrence (5) · Carcinoma, Non-Small-Cell Lung (4) · Melanoma (4) · Methylmalonic acidemia (4) · Propionic Acidemia (4) · Epstein-Barr Virus Infections (3) · Metabolic Diseases (3)
2019-nCoV Vaccine mRNA-1273 (26) · mRNA-1010 influenza vaccine (14) · mRNA-1345 respiratory syncytial virus vaccine (14) · pembrolizumab (13) · mRNA-1647 cytomegalovirus vaccine (9) · mRNA-1273.214 COVID-19 vaccine (8) · Influenza Vaccines (5) · COVID-19 Vaccines (4) · Sodium Chloride (3) · BNT162 Vaccine (2) · Carboplatin (2) · Methylmalonyl-CoA Mutase (2) · Paclitaxel (2) · Saline Solution (2) · Surgical Procedures, Operative (2)
United States (115) · United Kingdom (34) · Canada (29) · Australia (27) · Spain (22) · Japan (18) · France (17) · Germany (14) · Poland (14) · Chile (12) · Italy (12) · South Korea (12) · Argentina (11) · Taiwan (11) · Netherlands (10)
Anna Giuliano, PhD (1) · Benjamin Meyer, Dr. (1) · Gili Regev-Yochay, MD (1) · Heiner C. Bucher, Prof. Dr. med. (1) · Laura Esserman, MD (1) · Laura Gibson, MD (1) · Lesia K Dropulic, M.D. (1) · Lila J. Rutten, PhD (1) · Linda-Gail Bekker (1) · Saad Usmani, MD,MBA,FACP (1) · William Wood, MD, MPH (1) · Yusaku Michael Shino, MD (1)
PMID 31079849, PMID 35547849, PMID 36202997, PMID 36682364, PMID 38190492, PMID 38518789, PMID 39481241, PMID 40174609, PMID 32663912, PMID 32991794, PMID 33378609, PMID 33707061, PMID 34090865, PMID 34311780, PMID 34379915, PMID 34401888, PMID 34526698, PMID 34551225, PMID 34642699, PMID 34674742, PMID 34870630, PMID 34887572, PMID 35072628, PMID 35126362, PMID 35145311, PMID 35210606, PMID 35234868, PMID 35241844, PMID 35291289, PMID 35535503, PMID 35544369, PMID 35785530, PMID 35876706, PMID 35902817, PMID 36055877, PMID 36102707, PMID 36112399, PMID 36163093, PMID 36238717, PMID 36260859, PMID 36376733, PMID 36577040, PMID 37074202, PMID 37075127, PMID 37210308, PMID 37330602, PMID 37336877, PMID 37348519, PMID 37385888, PMID 37653342
2023 (14), 2025 (3), 5UM1AI148373-05 (2), 2015 (1)